Wednesday August 12, 2020

Biosimilar drugs offer a savings opportunity that we must take

A dramatic increase in the prescribing of cheaper biosimilar medicines is required to enable us to afford costly new cancer and other therapies

3rd March, 2019

Since 2010, the Irish health service has spent over €1 billion on two medicines alone: adalimumab (brand name: Humira) and etanercept (brand name: Enbrel). Both are complex biological medicines that are licensed to treat a variety of conditions ranging from rheumatoid arthritis and psoriatic arthropathy to inflammatory bowel disease including Crohn’s disease and ulcerative colitis.

The beneficial effects of these drugs are experienced by over 16,000 patients today, but this comes at a large...

Subscribe from just €1 for the first month!

Exclusive offers:

All Digital Access + eReader



Unlimited Access for 1 Month

Then €19.99 a month after the offer period.

Get basic
*New subscribers only
You can cancel any time.



€149 For the 1st Year

Unlimited Access for 1 Year

You can cancel any time.




90 Day Pass

You can cancel any time.

2 Yearly



Unlimited Access for 2 Years

This product does not auto-renew

Team Pass

Get a Business Account for you and your team

Related Stories

Many of us have achieved a new life balance that might just be the real ‘new normal’

Sharyn McAndrew | 2 months ago

Property firms such as QRE are dealing with the coronavirus lockdown by trying to maintain some normality in their day-to-day business

Conor Whelan | 3 months ago

Hardline opposition to EU solidarity in funding the cost of Covid-19 is driven by German allergy to ‘imprudent’ spending, and by Dutch politicians fearing the transfer of funds to southern countries would provoke a far-right backlash

Barry J Whyte | 4 months ago